Post-Market Winners: A Calm Trading Day Highlighted by a Notable Biotech Rise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy AMLX?
Source: NASDAQ.COM
DBV Technologies Surge: DBV Technologies S.A. experienced a dramatic 61.29% increase in after-hours trading after announcing successful results from its Phase 3 study of the VIASKIN Peanut patch for peanut-allergic children, reigniting investor interest.
Modular Medical Offering: Modular Medical, Inc. saw a modest gain of 3.53% amid ongoing investor analysis of its recent public offering announcement, which includes over 12 million shares priced at an effective cost of $0.38 per share.
Other Small Gains: Several other companies, including Co-Diagnostics, Elutia Inc., and Treace Medical Concepts, posted small increases in after-hours trading, attributed to light-volume activity rather than specific news.
Amylyx Pharmaceuticals Update: Amylyx Pharmaceuticals advanced 4.83% following its recent presentation of early Phase 1 trial data for AMX0114, which showed promising safety and tolerability, with further enrollment expected soon.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMLX
Wall Street analysts forecast AMLX stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.550
Low
15.00
Averages
21.67
High
28.00
Current: 13.550
Low
15.00
Averages
21.67
High
28.00
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amylyx Completes Last Participant Enrollment in LUCIDITY Trial for Avexitide
- Trial Enrollment Completion: Amylyx announced that the last participant has been randomized and dosed in the LUCIDITY trial, which enrolled a total of 78 participants, marking a significant milestone with topline data expected in Q3 2026, and a potential commercial launch of avexitide anticipated in 2027 if approved.
- Clinical Trial Design: The LUCIDITY trial is a 16-week, multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of avexitide in reducing Level 2 and Level 3 hypoglycemic events in adults post-Roux-en-Y gastric bypass surgery, aligning with FDA-agreed primary outcomes.
- Early Data Support: Previous Phase 1 and Phase 2 trials demonstrated statistically significant reductions in hypoglycemic events with avexitide, indicating its potential to improve patient quality of life and address the urgent need for effective treatments in post-bariatric hypoglycemia.
- Urgent Market Need: Post-bariatric hypoglycemia (PBH) affects approximately 8% of patients who undergo weight-loss surgery, highlighting a significant unmet medical need; the development of avexitide could not only fill this gap but also alleviate the healthcare burden associated with this chronic condition.
See More
Amylyx Pharmaceuticals Updates on Avexitide LUCIDITY Trial Progress
- Trial Progress: Amylyx Pharmaceuticals' LUCIDITY trial is nearly fully enrolled and expects to release top-line results for avexitide in Q3; this 16-week randomized, placebo-controlled study aims to evaluate the drug's efficacy in treating post-bariatric hypoglycemia, highlighting the company's potential in an area lacking approved therapies.
- Drug Mechanism and Market Need: Avexitide, as a first-in-class GLP-1 receptor antagonist, targets approximately 160,000 U.S. patients suffering from post-bariatric hypoglycemia, with prior trials demonstrating significant reductions in hypoglycemic events and supporting its FDA Breakthrough Therapy designation, underscoring its market relevance.
- Efficacy and Data Support: In a Phase II trial, avexitide achieved a 64% reduction in hypoglycemic events at the highest tested dose, with a p-value of 0.003, showcasing its clinical effectiveness and bolstering investor confidence in the drug's potential.
- Future Development Plans: Amylyx is also pursuing a long-acting GLP-1 receptor antagonist, AMX0318, and has reported positive signals in its Wolfram syndrome program, indicating the company's strategic commitment to expanding its product pipeline and addressing unmet medical needs.
See More
Amylyx Pharmaceuticals: 2026 Could Be Transformative Ahead of Avexitide Phase 3 Readout
- Clinical Trial Progress: Amylyx Pharmaceuticals announced at TD Cowen's 46th Annual Healthcare Conference that the LUCIDITY Phase 3 trial for avexitide was initiated in 2025, with enrollment expected to complete by March 2026; positive results could support a New Drug Application in 2027, highlighting the company's potential in treating post-bariatric hypoglycemia.
- Market Demand Analysis: Approximately 160,000 people in the U.S. currently suffer from post-bariatric hypoglycemia, with an incidence rate of about 8%, supported by over 2 million bariatric surgeries performed in the past decade, indicating a significant unmet medical need that could lay the groundwork for avexitide's market introduction.
- Efficacy Data Support: Previous clinical studies demonstrated that avexitide achieved a 52% and 66% reduction in level 2 and level 3 hypoglycemic events, respectively, showcasing its potential to improve patient quality of life and reinforcing its status as a breakthrough therapy.
- Future Development Plans: The company aims for avexitide commercialization in 2027 and is actively preparing the NDA submission materials, reflecting confidence in future market opportunities and responsiveness to patient needs, which is expected to positively impact the company's financial performance.
See More
Amylyx Pharmaceuticals Q4 2025 Earnings Call Insights
- Pipeline Advancement: Amylyx Pharmaceuticals made significant strides in 2025 by initiating the pivotal Phase III LUCIDITY trial for avexitide targeting post-bariatric hypoglycemia and nominating AMX0318 as a development candidate, indicating a strategic focus on rare diseases.
- Strong Financial Position: As of Q4 2025, the company reported $317 million in cash and marketable securities, down from $344 million in Q3, yet still ensuring a cash runway into 2028 to support future R&D and commercialization efforts.
- Optimized R&D Spending: The R&D expenses for Q4 were $21.2 million, primarily reflecting increased investment in avexitide clinical development while showing a decrease compared to the same period in 2024, demonstrating effective resource allocation.
- Clear Market Opportunity: Management highlighted that approximately 160,000 people in the U.S. suffer from post-bariatric hypoglycemia, with urgent market demand; preparations for the potential commercialization of avexitide are underway, targeting a 2027 launch to strengthen the company's market position.
See More
Amylyx (AMLX) Q4 2025 Earnings Call Transcript
See More
Amylyx Pharmaceuticals Q4 2025 Earnings Beat Expectations
- Earnings Beat: Amylyx Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding expectations by $0.04, indicating an improvement in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, the company held $317.0 million in cash, cash equivalents, and short-term investments, down from $344.0 million on September 30, 2025, reflecting its cash utilization in operations.
- Cash Runway Outlook: Based on current operating plans, Amylyx expects its cash runway to extend into 2028, providing financial stability for long-term growth and demonstrating management's confidence in future operations.
- Increased Market Attention: With the company's presentation at the Citi Annual Global Healthcare Conference, Amylyx is gaining increased market attention, potentially paving the way for future financing and partnership opportunities.
See More
Amylyx Completes Last Participant Enrollment in LUCIDITY Trial for Avexitide
- Trial Enrollment Completion: Amylyx announced that the last participant has been randomized and dosed in the LUCIDITY trial, which enrolled a total of 78 participants, marking a significant milestone with topline data expected in Q3 2026, and a potential commercial launch of avexitide anticipated in 2027 if approved.
- Clinical Trial Design: The LUCIDITY trial is a 16-week, multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of avexitide in reducing Level 2 and Level 3 hypoglycemic events in adults post-Roux-en-Y gastric bypass surgery, aligning with FDA-agreed primary outcomes.
- Early Data Support: Previous Phase 1 and Phase 2 trials demonstrated statistically significant reductions in hypoglycemic events with avexitide, indicating its potential to improve patient quality of life and address the urgent need for effective treatments in post-bariatric hypoglycemia.
- Urgent Market Need: Post-bariatric hypoglycemia (PBH) affects approximately 8% of patients who undergo weight-loss surgery, highlighting a significant unmet medical need; the development of avexitide could not only fill this gap but also alleviate the healthcare burden associated with this chronic condition.
See More
Amylyx Pharmaceuticals Updates on Avexitide LUCIDITY Trial Progress
- Trial Progress: Amylyx Pharmaceuticals' LUCIDITY trial is nearly fully enrolled and expects to release top-line results for avexitide in Q3; this 16-week randomized, placebo-controlled study aims to evaluate the drug's efficacy in treating post-bariatric hypoglycemia, highlighting the company's potential in an area lacking approved therapies.
- Drug Mechanism and Market Need: Avexitide, as a first-in-class GLP-1 receptor antagonist, targets approximately 160,000 U.S. patients suffering from post-bariatric hypoglycemia, with prior trials demonstrating significant reductions in hypoglycemic events and supporting its FDA Breakthrough Therapy designation, underscoring its market relevance.
- Efficacy and Data Support: In a Phase II trial, avexitide achieved a 64% reduction in hypoglycemic events at the highest tested dose, with a p-value of 0.003, showcasing its clinical effectiveness and bolstering investor confidence in the drug's potential.
- Future Development Plans: Amylyx is also pursuing a long-acting GLP-1 receptor antagonist, AMX0318, and has reported positive signals in its Wolfram syndrome program, indicating the company's strategic commitment to expanding its product pipeline and addressing unmet medical needs.
See More
Amylyx Pharmaceuticals: 2026 Could Be Transformative Ahead of Avexitide Phase 3 Readout
- Clinical Trial Progress: Amylyx Pharmaceuticals announced at TD Cowen's 46th Annual Healthcare Conference that the LUCIDITY Phase 3 trial for avexitide was initiated in 2025, with enrollment expected to complete by March 2026; positive results could support a New Drug Application in 2027, highlighting the company's potential in treating post-bariatric hypoglycemia.
- Market Demand Analysis: Approximately 160,000 people in the U.S. currently suffer from post-bariatric hypoglycemia, with an incidence rate of about 8%, supported by over 2 million bariatric surgeries performed in the past decade, indicating a significant unmet medical need that could lay the groundwork for avexitide's market introduction.
- Efficacy Data Support: Previous clinical studies demonstrated that avexitide achieved a 52% and 66% reduction in level 2 and level 3 hypoglycemic events, respectively, showcasing its potential to improve patient quality of life and reinforcing its status as a breakthrough therapy.
- Future Development Plans: The company aims for avexitide commercialization in 2027 and is actively preparing the NDA submission materials, reflecting confidence in future market opportunities and responsiveness to patient needs, which is expected to positively impact the company's financial performance.
See More
Amylyx Pharmaceuticals Q4 2025 Earnings Call Insights
- Pipeline Advancement: Amylyx Pharmaceuticals made significant strides in 2025 by initiating the pivotal Phase III LUCIDITY trial for avexitide targeting post-bariatric hypoglycemia and nominating AMX0318 as a development candidate, indicating a strategic focus on rare diseases.
- Strong Financial Position: As of Q4 2025, the company reported $317 million in cash and marketable securities, down from $344 million in Q3, yet still ensuring a cash runway into 2028 to support future R&D and commercialization efforts.
- Optimized R&D Spending: The R&D expenses for Q4 were $21.2 million, primarily reflecting increased investment in avexitide clinical development while showing a decrease compared to the same period in 2024, demonstrating effective resource allocation.
- Clear Market Opportunity: Management highlighted that approximately 160,000 people in the U.S. suffer from post-bariatric hypoglycemia, with urgent market demand; preparations for the potential commercialization of avexitide are underway, targeting a 2027 launch to strengthen the company's market position.
See More
Amylyx (AMLX) Q4 2025 Earnings Call Transcript
See More
Amylyx Pharmaceuticals Q4 2025 Earnings Beat Expectations
- Earnings Beat: Amylyx Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding expectations by $0.04, indicating an improvement in financial performance despite ongoing losses.
- Cash Position: As of December 31, 2025, the company held $317.0 million in cash, cash equivalents, and short-term investments, down from $344.0 million on September 30, 2025, reflecting its cash utilization in operations.
- Cash Runway Outlook: Based on current operating plans, Amylyx expects its cash runway to extend into 2028, providing financial stability for long-term growth and demonstrating management's confidence in future operations.
- Increased Market Attention: With the company's presentation at the Citi Annual Global Healthcare Conference, Amylyx is gaining increased market attention, potentially paving the way for future financing and partnership opportunities.
See More
